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ntracranial dural arteriovenous fistulae (dAVFs) are typified by pathological anastomoses between meningeal arteries and dural venous sinuses or cortical veins. These fistulae frequently reside within the dural leaflets surrounding a venous sinus, characteristically at the transverse-sigmoid junction but also at the cavernous sinus (CS), superior sagittal sinus, anterior cranial fossa, tentorium, and other locations. dAVFs are distinguished from their pial counterparts (eg, arteriovenous malformations) by their arterial supply from vessels that perfuse the dura mater and lack of a parenchymal nidus. 1 dAVFs are rare lesions, accounting for 10% to 15% of all intracranial vascular malformations: 6% of supratentorial and 35% of infratentorial vascular malformations. 2 Most frequently, dAVFs affect patients in their middle-to-later years of life (eg, 50-60 years of age). 3 Less commonly, dAVFs occur in younger age groups, including children. There is neither a clear sex predilection nor genetic component to these lesions. Clinical manifestations vary widely and depend on both the hemodynamic properties and location of the fistula. Multiple classification systems have been proposed in an effort to predict which dAVFs are at high risk for new neurological events. Most of these schemes stratify risk based on angiographic appearance of the dAVFs, in particular involvement of a venous sinus and presence or absence of retrograde cortical venous drainage (CVD). Other schemes combine angiographic appearance with mode of presentation, given the impact symptoms related to intracerebral hemorrhage (ICH) and nonhemorrhagic neurological deficits (NHND) have on dAVF natural history. [4] [5] [6] In the following review and synthesis, the authors describe the pathophysiology, classification, mode of presentation, imaging characteristics, natural history, and therapeutic armamentarium for intracranial dAVFs. Particular attention will be given to recent evidence that certain clinical and angiographic features of dAVFs can be used to help stratify risk of future ICH and NHND in an effort to guide treatment decision-making, as well as advances in the manner in which these lesions can be treated. Given that carotid-cavernous fistulas (CCFs) have a variety of differentiating features related to their unique drainage pattern into the CS, this subset of dAVFs will be examined separately.
Pathophysiology
The pathological mechanisms underlying dAVF formation remain enigmatic. While the majority of dAVFs are acquired in an idiopathic fashion, a smaller subset results from traumatic head injury, infection, previous craniotomy, tumors, or dural venous sinus thrombosis. 3, [7] [8] [9] Most authorities think that dAVFs arise from progressive stenosis or occlusion of a dural venous sinus. The correlation between patients with dAVFs and hereditary thrombotic diseases (eg, Factor V Leiden, Protein C/S deficiency) supports this hypothesis. 10, 11 As venous sinus pressure increases, meningeal arteries develop fistulous connections with the dural sinus or cortical veins. This may occur via enlargement of preexisting physiological shunts or de novo fistula development from neoangiogenesis. 1, 12, 13 The end result is a complex network of venous tributaries under arterial pressure. With worsening sinus outflow obstruction and venous hypertension, the normal antegrade pattern of venous flow is reversed, resulting in retrograde flow through cortical veins (termed cortical venous drainage, or CVD) that can produce venous hypertension within the surrounding brain.
dAVF formation is a dynamic process; fistula hemodynamics may change over time after recanalization of the thrombosed sinus, recruitment of additional external carotid artery (ECA) feeders (with potential upconversion from a dAVF without CVD to a higher risk dAVF with CVD), or spontaneous thrombosis (with complete angiographic resolution of the dAVF). Ultimately, this pathological entity is capable of producing hemorrhage or NHND that can lead to substantial neurological morbidity and mortality. ICH is thought to occur from rupture of fragile arterialized parenchymal veins as a result of unrelenting venous reflux and cortical venous hypertension. 3, 14 While the precise underlying mechanisms governing NHND are not well established, the resulting venous congestion from dAVFs with CVD likely prevents the adequate arterial delivery of oxygen to vital tissues, with the inability to remove toxic waste products. 15, 16 This leads to a collapse of normal cellular metabolism and produces a functional impairment of the involved cerebral tissues. As a result of this pathological cascade, CVD is an ominous radiographic feature that portends a higher likelihood of ICH or NHND. 10, 17 CCFs comprise a unique subset of intracranial dAVFs that involve an abnormal communication between the internal carotid artery (ICA) or ECA and the CS. 18 These lesions may be further defined based on their underlying pathogenesis (spontaneous versus traumatic), angioarchitecture (direct shunt from cavernous ICA, branches of cavernous ICA, meningeal branches of ECA, or combinations thereof), and hemodynamics (high flow versus low flow). Most commonly, direct CCFs occur at the proximal horizontal intracavernous ICA segment because of trauma involving the vessel wall (eg, skull base fracture or iatrogenic) or rupture of an aneurysm involving the cavernous ICA segment. This results in a highflow fistula between the ICA and CS. Less frequently, direct fistulas occur spontaneously via conditions that predispose to weakness of the cavernous ICA wall (eg, connective tissue disorders). Indirect CCFs are typically low-flow lesions that occur spontaneously. A variety of medical comorbiditiesincluding postmenopausal state, pregnancy, diabetes mellitus, collagen vascular disease, and hypertension-may predispose to the formation of indirect CCFs.
It should be noted that while CCFs have long been considered a distinct pathological entity from dAVFs, the 2 lesions share many similar pathophysiological features. While direct CCFs-for the reasons outlined above-indeed encompass their own unique category, indirect CCFs represent dAVFs of the parasellar region with a relationship to the CS. For this reason, many authorities advocate changing the nomenclature of the indirect CCFs in favor of the more accurate description of parasellar dAVFs.
Classification
The simplest and most commonly used scheme for differentiating dAVFs is the Borden-Shucart classification. 17 Using this system, dAVFs are distinguished based on venous drainage characteristics-especially the absence of CVD (Type I) or presence of CVD (Types II and III; Table) . Borden-Shucart Type I fistulae harbor dural arteries that drain exclusively into a dural sinus with antegrade venous flow ( Figure 1A ). BordenShucart Type II fistulae drain into a dural sinus with venous flow that is both antegrade into the dural sinus and retrograde into cortical veins (ie, CVD; Figure 1B ). Borden-Shucart Type III fistulae drain exclusively into cortical veins in a retrograde fashion (ie, CVD; Figure 1C ). Type II and III fistulae are considered high grade because of the presence of CVD and the impact this venous drainage pattern has on natural history (see below). These lesions may be further subcategorized as having a single fistula (subtype a) or multiple fistulae (subtype b). 17 The Cognard classification (Table) is predicated on shunt location, venous drainage characteristics, and venous outflow angioarchitecture. 10 Cognard type I and IIa dAVFs are analogous to Borden-Shucart type I fistulae (no CVD), with Type I lesions draining antegrade into a dural sinus and Type II lesions draining retrograde into a venous sinus. Type IIb fistulae drain antegrade into a venous sinus and have venous reflux into cortical veins (CVD). Type II a+b fistulae drain retrograde into a dural sinus and have venous reflux into cortical veins (CVD). Type III dAVFs drain directly into cortical veins (CVD). Type IV fistulae drain directly into cortical veins (CVD), but also display venous ectasia. Type V fistulae drain exclusively into spinal perimedullary veins. Type IIb through Type V fistulae are considered high grade given that all contain CVD and, therefore, have more aggressive natural history (see below).
Zipfel et al 6 proposed a modification to the aforementioned Borden-Shucart classification scheme based on new natural history data, indicating that mode of presentation markedly impacts future risk of ICH and NHND (Table) . This new system divides Borden-Shucart Type II and III dAVFs into 2 categories: (1) lesions presenting with asymptomatic CVD (ie, no symptoms or symptoms related to increased sinus flow including tinnitus or ophthalmologic phenomena)-Type 2A and 3A; and (2) lesions presenting with symptomatic CVD (ie, symptoms related to cortical venous hypertension including ICH and NHND)-Type 2S and 3S. 6, 19 By integrating angiographic appearance (presence or absence of CVD) and mode of presentation (asymptomatic versus symptomatic CVD) into a single scheme, this classification system more accurately predicts risk of future hemorrhagic and nonhemorrhagic neurological events and, therefore, affords improved risk stratification to guide appropriate timing and manner of dAVFs treatment.
While the Borden-Shucart, Cognard, and Zipfel classification systems can be applied to CCFs, the most frequently used scheme for these particular dAVFs is the Barrow classification. 18 In this 4-type angiographic classification system, CCFs are differentiated based on whether a direct, high-flow connection occurs between the cavernous ICA and CS (as opposed to an indirect, low-flow dural shunt) and whether the fistula is supplied by the ICA, ECA, or both (Table I in 
Mode of Presentation
All patients suspected of harboring a dAVF require a full neurological examination, including an ophthalmological evaluation (especially if a CCF/parasellar dAVF is suspected) and auscultation for a flow-related intracerebral bruit. The clinical Figure 1 . Borden-Shucart classification of intracranial intracranial dural arteriovenous fistulae. In Type I fistulae (A), progressive venous sinus stenosis or occlusion results in venous congestion and anastomoses between meningeal arteries (eg, transosseous feeders from the occipital artery, as depicted here) and a dural venous sinus (eg, transverse sigmoid junction, as depicted here). Venous flow is entirely anterograde, and cortical venous drainage (CVD) is absent. In Type II fistulae (B), progressively worsening venous hypertension results in both anterograde (into sinus) and retrograde (CVD) venous outflow. In Type III lesions (C), a meningeal artery shunts directly into a cortical vein (with CVD). Venous outflow, by definition, is entirely retrograde. In this example, ethmoidal branches from the ophthalmic artery shunt directly into a cortical frontal vein, resulting in a venous varix. findings combined with a thorough history and physical form the basis for the efficient use of diagnostic imaging studies to definitively identify the underlying dAVF. Patients with dAVFs present in 3 primary ways: (1) aggressive symptoms such as ICH and NHND related to cortical venous hypertension, which only develop in dAVFs with CVD (eg, BordenShucart Type II and III); (2) more benign symptoms such as tinnitus and ophthalmologic phenomenon related to increased sinus drainage, which can occur in any dAVF having venous sinus drainage; and (3) incidental.
ICH from a dAVF often causes sudden-onset headache with varying degrees of neurological disability related to the location and size of the ICH. These events are the result of rupture of delicate, arterialized leptomeningeal veins or hemorrhagic transformation of cortical venous congestion. NHNDs usually develop more gradually over days to weeks and result from focal or global cortical venous hypertension that produces varying degrees of cerebral ischemia. 15, 16 Reported NHNDs related to dAVFs include seizures, focal cortical deficits, cranial nerve palsies, trigeminal neuralgia, thalamic or cortical dementia, Parkinsonism, cerebellar dysfunction, dysmetria, paresthesias, myelopathy, quadriparesis, aphasia or dysphasia, apraxia, apathy, failure to thrive, and symptoms related to increased pressure, including headache, nausea, and vomiting. 1, 17, [19] [20] [21] [22] [23] The specific nature of the NHNDs depend on the location of the offending dAVF. For example, dAVFs that drain directly into the superior sagittal sinus or deep venous system (eg, vein of Galen) often manifest with symptoms related to global venous congestion/hypertension, such as seizures, CSF obstruction, papilledema, or dementia. 14, 24 Brain stem dAVFs, although uncommon, often cause symptoms related to cranial neuropathies or quadriparesis. 14, 25 More benign symptoms caused by increased venous sinus drainage are dependent on dAVF location. For instance, dAVFs located in the anterior cranial fossa are often fed by ethmoidal branches off the ophthalmic artery and drain into the CS venous system. 21, 26 Ophthalmological manifestations, including visual deterioration, proptosis, chemosis, cranial nerve palsies, and CS syndrome, are common presenting features of these dAVFs because of their intimate association with the orbit.
14,21,27 dAVFs in the CS and sella region (eg, CCFs/ parasellar dAVFs) similarly often present with ophthalmological symptoms related to CS syndrome. dAVFs in the middle cranial fossa are typified by drainage into the transverse or sigmoid venous sinuses. 21, 28 Given their close proximity to the auditory apparatus, pulsatile tinnitus is a common symptom from these fistulae.
21

Imaging
Initial radiographic evaluation typically includes cross-sectional studies from noncontrast head computed tomography and magnetic resonance imaging. While head computed tomography alone cannot make the diagnosis of dAVFs, this modality can detect dAVF-related ICH and vasogenic edema caused by cortical venous hypertension. Because venous varices are often the source of hemorrhage, the hemorrhage can be remote from the actual location of the arteriovenous shunt. 29 Magnetic resonance imaging is helpful for delineating dAVF anatomy given its superior resolution and ability to define surrounding neurological structures. Flow voids from large arterialized draining veins and varices may be visualized on T2-weighted imaging (Figure 3 ). Fistula-related microhemorrhages are often more pronounced on T2*/gradient echo magnetic resonance sequences. Post-gadolinium T1-weighted imaging may show dilated leptomeningeal and medullary vessels, venous ectasia, parenchymal enhancement, and venous sinus occlusion or thrombosis. 30 Hyperintensities on T2-weighted and fluid-attenuated inversion recovery sequences suggests vasogenic edema because of venous hypertension. As an example, Holekamp et al 19 recently described a series of patients with rapidly progressive thalamic dementia resulting from dAVFs with deep venous drainage into the vein of Galen who demonstrated pronounced bithalamic edema on T2/fluid-attenuated inversion recovery sequences (Figure 4) . In all cases, treatment of the fistula resulted in radiographic resolution of these magnetic resonance imaging abnormalities. In general, any serpiginous arrangement of vessels surrounding a dural sinus warrants further evaluation with dynamic vascular imaging.
Catheter-based cerebral angiography (eg, digital subtraction angiography) remains the gold standard for dAVF diagnosis. Digital subtraction angiography is essential for delineating fistula angioarchitecture, location and number of fistulae, anatomy of the ECAs and their dural branches, presence or absence of CVD, degree of dural sinus stenosis/ occlusion, and presence of venous ectasia ( Figure 5 ). 31 Venous congestion may be angiographically quantified not only by the presence of CVD, but also by the number and pattern of tortuous, engorged leptomeningeal veins (pseudophlebitic pattern) 32 seen in the venous phase. Superselective angiography may also be required to identify the area of convergence of the feeding dural arteries and the origin of the draining vein.
Natural History
Low-Grade dAVFs (ie, Fistulae Without CVD)
Several studies have documented that dAVFs without CVD, including Borden-Shucart Type I, Zipfel Type 1, and Cognard Type I and IIa have a benign natural history and rarely cause ICH or NHND. [33] [34] [35] [36] The first to document this clinical course was Satomi et al, 33 who retrospectively examined 112 patients with Borden-Shucart Type I dAVFs that were either treated conservatively or with palliative endovascular therapy (ie, dAVFs flow was reduced but not eliminated). They observed one symptomatic ICH and no NHND over a mean follow-up of 2.3 years and calculated an annual neurological event rate of 0.6% and a mortality rate of 0.0%. Shah et al 34 retrospectively examined 23 Borden-Shucart Type I dAVFs that were treated conservatively or with palliative endovascular therapy. They observed no ICH or NHND over a mean follow-up of 5.6 years. They calculated an annual rate of ICH or NHND of 0.0% and an annual mortality rate of 0.0%. Gross and Du 35 retrospectively examined 24 Borden-Shucart Type I dAVFs. They reported no cases of ICH, NHND, or death during 409 lesion-years of follow-up. 35 Based on these 3 studies, the annual rate of new neurological events for dAVFs without CVD is 0.0% to 0.6%, and the annual mortality rate for these lesions is 0.0%.
Notably, dAVFs without CVD (eg, Borden-Shucart Type I) can convert to dAVFs with CVD (eg, Borden-Shucart Type II and III) over time 10, 33, 34 -a phenomenon caused by progressive stenosis or thrombosis of venous outlets, increased arterial flow, or recruitment or extension of the fistulous connection. Cognard et al 10 
documented this upconversion in 7 patients
with dAVFs who were treated conservatively or with palliative endovascular therapy. Importantly, they noted that each of these dAVF transformations occurred in the setting of new or recurrent neurological symptoms. Satomi et al 33 documented upconversion in 2 patients who were treated conservativelyboth of which were discovered at the time of change in patient symptoms (one symptomatic ICH and one spontaneous resolution of tinnitus). Shah et al 34 documented upconversion of 2 patients who were treated with palliative endovascular therapy-both of which were discovered at the time of recurrent tinnitus. They calculated an annual rate of upconversion from dAVFs without CVD to dAVFs with CVD of 0.8%. Based on these reports, it should be emphasized that prompt angiographic reevaluation is warranted when any change in a patient's symptoms (either deterioration or improvement) occurs. 
High-Grade dAVFs (ie, Fistulae With CVD)
dAVFs with CVD including Borden-Shucart Type II and III, Zipfel Type 2A, 2S, 3A, and 3S, and Cognard Types IIb, IIa+b, III-V have an aggressive natural history and frequently develop ICH or NHND if untreated. 3, 6, 10, 17, 37 This was first suggested by Duffau et al 38 who retrospectively examined 20 patients with Borden-Shucart Type II and III dAVFs and observed a rebleeding rate of 35% after an average followup of only 20 days. van Dijk et al 27 retrospectively examined 20 patients with Borden-Shucart Type II and III dAVFs who either refused treatment or underwent therapy that did not eliminate the CVD. They observed an annual neurological event rate of 15.0% and an annual mortality rate of 10.4%. Based on these important early studies, it became clear that patients diagnosed with dAVFs with CVD are at substantial risk of ICH, NHND, and death and that the majority of these patients should strongly consider treatment of their dAVFs to eliminate this risk.
Notably, the majority of patients in the Duffau et al 38 and van Dijk et al 25 cohorts presented with aggressive symptoms of ICH or NHND (100% and 80%, respectively), raising the question of whether dAVFs with CVD presenting without such symptoms (ie, incidentally or with more benign symptoms of increased venous sinus flow such as tinnitus) carried similar risk for ICH or NHND. Söderman et al 4 retrospectively examined 81 patients with Borden-Shucart Type II and III dAVFs with time at risk of 49.6 patientyears. They observed a significant difference in the annual rate of new neurological events between patients presenting ICH versus patients presenting without ICH-7.4% versus 1.5%, respectively. Strom et al 5 retrospectively examined 28 patients with Borden-Shucart Type II and III dAVFs who either refused treatment, underwent therapy that did not eliminate the CVD, or underwent delayed treatment that eliminated the CVD. They observed a significant difference in the annual rate of new neurological events between patients presenting with ICH or NHND (median follow-up of 9.7 months) versus patients presenting without ICH or NHND (median follow-up of 31.4 months)-19.0% versus 1.4%, respectively. They also reported a significant difference in annual mortality rates between the 2 cohorts-3.8% versus 0.0%, respectively. Gross and Du 35 pooled their cohort of Borden-Shucart Type II and III dAVFs with other available case series from the literature and reported on their clinical course after ≈400 patient-years of follow-up. They observed a significant difference in the annual rate of ICH between patients presenting with ICH versus patients presenting with NHND versus patients presenting incidentally or with more benign symptoms of increased sinus drainage-46% versus 10% versus 2%, respectively. From these reports, an association between the mode of presentation and natural history of dAVFs with CVD has become apparent. Specifically, patients harboring dAVFs with CVD who present with symptoms of either ICH or NHND (ie, symptomatic CVD) have a greater likelihood of suffering hemorrhagic or nonhemorrhagic neurological injury compared with those presenting incidentally or with symptoms of increased sinus drainage (ie, asymptomatic CVD).
Finally, 2 studies have recently examined an angiographic factor that also impacts risk of new neurological events in patients having dAVFs with CVD. Bulters et al 8 retrospectively examined 75 dAVFs with CVD and assessed their clinical course from time of diagnosis to definitive treatment (71 patients) or last follow-up (4 patients), with an average follow-up of 1.2 years. They observed a nonsignificant trend toward increased annual risk of hemorrhage in patients presenting with aggressive symptoms of ICH or NHND versus patients presenting incidentally or with more benign symptoms of increased sinus drainage-20% and 22% versus 4.3%, respectively. Interestingly, they noted a statistically significant increase in annual risk of hemorrhage between patients with dAVFs having venous ectasia versus those with dAVFs without venous ectasia-19.0% versus 1.4%, respectively. The pooled analysis by Gross and Du 35 also examined the impact of venous ectasia on dAVFs natural history. They found a statistically significant increase in hemorrhagic risk in patients with dAVFs having venous ectasia by both random effects (incidence risk ratio of 6.07; 95% confidence interval, 2.12-10.0) and fixed-effects (incidence risk ratio of 6.07; 95% confidence interval, 2.12-10.0) models.
Taken together, these data on the natural history of dAVFs with CVD underscores the necessity of treating these higher risk vascular lesions in most patients. As compared with other well-known cerebrovascular lesions, such as intracerebral aneurysms (eg, annual risk of rupture for <7 mm of ≈<1% per year) 39 and pial arteriovenous malformations (eg, annual risk of rupture ≈1% to 4% per year), 40, 41 dAVFs with CVD likely comprise the most dangerous group of cerebrovascular lesions (from a natural history perspective) that neurointerventional surgeons treat.
Treatment Options
The natural history of dAVFs with CVD that present with aggressive symptoms such as ICH and NHND is poorannual rate of ICH and NHND is 7.4% to 19.0% and the annual rate of mortality is 3.8%. 6 For this reason, urgent treatment of these lesions by modalities expected to immediately eliminate this risk (endovascular, surgical, or combination) is recommended for most patients. The natural history of dAVFs with CVD presenting incidentally or with more benign symptoms, such as tinnitus or ophthalmologic phenomena, is less aggressive but still significant-annual rate of ICH and NHND is 1.4% to 1.5%, and the annual rate of mortality is 0.0%. 6 For this reason, treatment is often recommended in properly selected patients (ie, patients without major comorbidities with prolonged life expectancy); however, treatment timing can be more elective and the modalities considered can be expanded to include radiosurgery, even though this treatment typically takes 1 to 3 years to achieve complete dAVF obliteration. 42 In contradistinction, the natural history of dAVFs without CVD is benign-annual rate of ICH and NHND is 0.0% to 0.6%, and the annual rate of mortality is 0.0%. 6 Patients harboring these lesions should, therefore, be treated primarily based on their presenting symptoms. Those presenting incidentally should be managed conservatively with repeat vascular imaging studies performed if new symptoms develop (eg, tinnitus, ophthalmologic symptoms, seizure, focal neurological deficit) because the onset of new symptoms referable to the dAVFs could represent upconversion to a lesion with CVD and a more aggressive clinical course. Those presenting with symptoms of tinnitus or ophthalmologic phenomena should be treated based on the severity of their symptoms and the impact of these symptoms on the patients' quality of life. When treated, the primary goal of therapy is to reduce dAVF flow enough to eliminate the intolerable symptoms rather than to achieve complete dAVF obliteration, though the latter if achieved provides the additional benefit of eliminating the risk of recurrent symptoms and the possibility of upconversion to a dAVF with CVD. Given the complexity of these lesions and the many therapeutic options available, dAVF patients are likely best treated in centers where therapeutic decisions are made in a collaborative fashion by an experienced team of neurosurgeons, endovascular specialists, and radiosurgeons. In general, options for dAVF treatment include conservative therapy, endovascular embolization ( Figure I in the online-only Data Supplement), microsurgical disconnection of the CVD ( Figure II in the online-only Data Supplement), stereotactic radiosurgery, or combinations thereof. These treatment options-with their attendant risks and outcomes-are discussed in the onlineonly Data Supplement.
Conclusions
Intracranial dAVFs are a heterogeneous group of vascular malformations with their own distinct pathobiology, symptomatology, angioarchitecture, natural history, and treatment options. While many classification schemes exist to stratify risk of hemorrhage and ischemic neurological deficits, the presence of CVD is an ominous sign that portends a high risk of adverse neurological sequelae. More recently, patients with dAVFs and CVD presenting with aggressive symptoms have been shown to be at particularly high risk for ICH and NHND, especially if venous ectasia is present. As such, these patients should be treated urgently with endovascular or microsurgical therapy, with the primary goal of eliminating the CVD and a secondary goal of completely obliterating the dAVFs. In contrast, patients with dAVFs and CVD without aggressive symptoms or venous ectasia have a lower risk of ICH and NHNDs. Though treatment is advisable for most of these patients, endovascular or microsurgical therapy can be pursued in a more elective fashion. In patients with major comorbidities, short life expectancy, or complex vascular anatomy that increases the risk of dAVF treatment, however, the best management may be stereotactic radiosurgery or close observation. Finally, patients having dAVFs without CVD have a benign natural history and are, therefore, only treated if they develop intolerable symptoms, such as tinnitus or orbital phenomena. In patients with dAVFs without CVD who are managed without neurosurgical intervention (eg, no embolization, stereotactic radiosurgery, microsurgery, or combinations thereof), close clinical follow-up is appropriate as any change in symptoms (including resolution of previous symptoms) should warrant prompt angiographic reevaluation to determine if the lesion has converted to a dAVF with CVD-an upconversion that should prompt strong consideration for dAVF intervention to eliminate the risk associated with the newly acquired CVD.
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